In addition to producing cell therapies for PAH, Northern Therapeutics has produced cell therapies for Sepsis.

Sepsis is a common and frequently fatal condition characterized by a dysregulated host response to infection and organ dysfunction [1]. This means that the body’s intense inflammatory response to an infection causes collateral damage to its own tissues and organs in response. A devastating and potentially lethal condition, sepsis is one of the leading causes of patient death in the intensive care unit (ICU) of hospitals in the United States [2]. Current sepsis management is limited to early goal-directed resuscitation, antibiotic therapy, glycemic control, and recombinant activated protein C for patients with severe sepsis and high risk for death by clinical assessment [3]. Infectious etiologies, such as sepsis and pneumonia, are leading causes of acute respiratory distress syndrome (ARDS) [4].

Mesenchymal stem cells (MSCs) are a type of adult somatic stem cells that can be isolated from various sources and expanded in culture. There is considerable evidence that MSCs may be “immune-privileged”, permitting their use in allo-transplantation (i.e., cells from another individual) without the need for immunosuppressive therapy [5]. The use of allogeneic cells makes it feasible for MSCs to be delivered as an “off-the-shelf” product for the treatment of acute and chronic disorders. Northern Therapeutics is actively working on developing a next generation MSC therapy for chronic diseases such as pulmonary arterial hypertension, and acute inflammatory conditions such as sepsis and adult respiratory distress syndrome (ARDS).

If you want to learn more about the Sepsis cell therapy, contact Northern Therapeutics at +1 343 291 1196 / email: